For example, Delta-like ligand 3 (DLL3), an inhibitory Notch ligand, is the target of a plethora of clinical therapeutics in SCLC and is reported to exhibit high expression in SCLC-A tumors (5). This evidence concerns the gene DLL3 and small cell lung carcinoma.